Orantinib Completed Phase 1 Trials for Unspecified Adult Solid Tumor, Protocol Specific Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00024206SU6668 in Treating Patients With Advanced Solid Tumors